on012380 and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

on012380 has been researched along with Leukemia--Myelogenous--Chronic--BCR-ABL-Positive* in 5 studies

Reviews

2 review(s) available for on012380 and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

ArticleYear
[New horizon of chronic myelogenous leukemia].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Jan-28, Volume: 65 Suppl 1

    Topics: Antineoplastic Agents; Benzene Derivatives; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Thiazoles

2007
[Novel anti-CML agents beyond imatinib].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2007, Volume: 48, Issue:6

    Topics: Adenosine Triphosphate; Aniline Compounds; Antineoplastic Agents; Benzamides; Benzene Derivatives; Binding Sites; Binding, Competitive; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles

2007

Other Studies

3 other study(ies) available for on012380 and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

ArticleYear
Targeted therapy and the T315I mutation in Philadelphia-positive leukemias.
    Haematologica, 2007, Volume: 92, Issue:4

    Topics: Adenosine Triphosphate; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Benzene Derivatives; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Hydrogen Bonding; Hydroxamic Acids; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Naphthalenes; Panobinostat; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Structure-Activity Relationship; Threonine; Vorinostat

2007
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
    Proceedings of the National Academy of Sciences of the United States of America, 2005, Feb-08, Volume: 102, Issue:6

    Imatinib, which is an inhibitor of the BCR-ABL tyrosine kinase, has been a remarkable success for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemias (CMLs). However, a significant proportion of patients chronically treated with imatinib develop resistance because of the acquisition of mutations in the kinase domain of BCR-ABL. Mutations occur at residues directly implicated in imatinib binding or, more commonly, at residues important for the ability of the kinase to adopt the specific closed (inactive) conformation to which imatinib binds. In our quest to develop new BCR-ABL inhibitors, we chose to target regions outside the ATP-binding site of this enzyme because these compounds offer the potential to be unaffected by mutations that make CML cells resistant to imatinib. Here we describe the activity of one compound, ON012380, that can specifically inhibit BCR-ABL and induce cell death of Ph+ CML cells at a concentration of <10 nM. Kinetic studies demonstrate that this compound is not ATP-competitive but is substrate-competitive and works synergistically with imatinib in wild-type BCR-ABL inhibition. More importantly, ON012380 was found to induce apoptosis of all of the known imatinib-resistant mutants at concentrations of <10 nM concentration in vitro and cause regression of leukemias induced by i.v. injection of 32Dcl3 cells expressing the imatinib-resistant BCR-ABL isoform T315I. Daily i.v. dosing for up to 3 weeks with a >100 mg/kg concentration of this agent is well tolerated in rodents, without any hematotoxicity.

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzamides; Benzene Derivatives; Cell Death; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Molecular Structure; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Proteins

2005
New leukemia drug shows promise against Gleevec resistance.
    Drug discovery today, 2005, Apr-01, Volume: 10, Issue:7

    Topics: Antineoplastic Agents; Benzamides; Benzene Derivatives; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines

2005